Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
https://www.zacks.com/stock/news/2251363/candel-cadl-up-on-upbeat-data-from-pancreatic-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251363
Apr 05, 2024 - Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
0
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
https://www.zacks.com/stock/news/2252667/is-it-a-good-idea-to-invest-in-adma-biologics-adma-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252667
Apr 09, 2024 - Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.
0
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
https://www.zacks.com/stock/news/2253377/lisata-s-lsta-lsta1-gets-fda-orphan-drug-tag-for-osteosarcoma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253377
Apr 10, 2024 - The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.
0
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
https://www.zacks.com/stock/news/2254638/astrazeneca-s-azn-fasenra-gets-fda-nod-for-asthma-in-kids?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254638
Apr 12, 2024 - The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
0
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
https://www.zacks.com/stock/news/2258578/roche-rhhby-alecensa-wins-fda-nod-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2258578
Apr 19, 2024 - Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
0
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
https://www.zacks.com/stock/news/2263560/sage-therapeutics-sage-q1-earnings-miss-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2263560
Apr 26, 2024 - Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
0
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
https://www.zacks.com/stock/news/2267221/sarepta-srpt-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267221
May 02, 2024 - Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
0
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
https://www.zacks.com/stock/news/2267310/moderna-mrna-q1-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2267310
May 02, 2024 - Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
0
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
https://www.zacks.com/stock/news/2267317/jazz-jazz-q1-earnings-sales-fall-short-of-estimates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2267317
May 02, 2024 - Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
0
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
https://www.zacks.com/stock/news/2269767/axsome-axsm-q1-loss-widens-y-y-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2269767
May 07, 2024 - Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
0